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Accumulating evidence indicate a role for the immune system particularly inﬂammation and autoimmunity in the aeti-
ology of major psychiatric disorders such as depression and schizophrenia. In this paper, we discuss some of the key
advances in immunopsychiatry in order to highlight to psychiatrists and other health professionals how an increased
understanding of this ﬁeld might enhance our knowledge of illness mechanism and approaches to treatment. We present
a brief overview of clinical research that link inﬂammation and autoimmunity with depression and psychosis, including
potential role of inﬂammation in treatment response, current evidence for the effectiveness of immune-modulating
treatment for depression and psychosis, and possible role of inﬂammation in common physical comorbidities for
these disorders such as coronary heart disease and diabetes mellitus. Gaining a better understanding of the role of
immune system could be paradigm changing for psychiatry. We need collaborations between clinicians and scientists
to deliver high-quality translational research in order to fully realise the clinical potential of this exciting and rapidly
expanding ﬁeld.
Received 11 November 2016; Revised 28 February 2017; Accepted 1 March 2017
Key words: Autoimmunity, autoantibody, cytokine, depression, immune system, immunopsychiatry, inﬂammation,
mental disorders, psychiatry, schizophrenia.
Introduction
There are intricate interactions between the immune
system and the brain that may offer new mechanistic
understanding and insights for novel therapies for psy-
chiatric disorders. In particular, proinﬂammatory cyto-
kines and circulating autoantibodies can inﬂuence the
brain leading to changes in mood, cognition and
behaviour; so may be relevant for the pathogenesis
and treatment of depression, psychosis and other
major psychiatric disorders (Raison et al. 2006;
Dantzer et al. 2008; Khandaker et al. 2015). In this
paper, we present a brief overview of clinical research
that link inﬂammation and autoimmunity with depres-
sion and psychosis. We discuss potential role of
inﬂammation in treatment response, current evidence
for the effectiveness of immune-modulating treatment
for depression and psychosis, and possible role of
inﬂammation in common physical comorbidities for
these disorders. Our aim is to inform psychiatrists
and other health professionals about a few key
advances (see Textbox) in the ﬁeld of immunopsychia-
try that could impact on clinical practice rather than
providing a comprehensive literature review regarding
the immune system and mental disorders. Unless spe-
ciﬁed otherwise, in this context inﬂammation refers to
chronic, low-grade systemic inﬂammation as reﬂected
by increased concentrations of circulating inﬂamma-
tory markers in peripheral blood such as cytokines
and acute phase proteins, rather than inﬂammation
in the classical sense, which is clinically manifest by
the so-called cardinal signs.
Evidence for a role of inﬂammation in depression
Depression is common in people with a chronic inﬂam-
matory illness such as rheumatoid arthritis (Dickens &
Creed, 2001). About 30–50% of patients with hepatitis
C virus develop depression following treatment with
interferon (Bonaccorso et al. 2002), which is a potent
inducer of inﬂammatory cytokines. These clinical
observations provide clues that inﬂammation may
play a role in depression. Indeed, inducing inﬂamma-
tion in healthy volunteers in experimental setting
with a typhoid vaccine leads to depressive symptoms
and reduced cognitive performance, which is mediated
by increase in circulating interleukin 6 (IL-6) levels
(Harrison et al. 2009), a pleiotropic, proinﬂammatory
cytokine. Furthermore, systematic reviews and meta-
analyses of cross-sectional studies have conﬁrmed
that the levels of circulating proinﬂammatory cyto-
kines such as IL-6, IL-1β, tumour necrosis factor
alpha (TNF-α) and acute phase proteins such as
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C-reactive protein (CRP) are elevated in acutely
depressed patients, which are largely normalised
after recovery (Howren et al. 2009; Haapakoski et al.
2015; Goldsmith et al. 2016). However, a limitation
of the cross-sectional studies is that they cannot
determine whether increase in inﬂammatory markers
is a cause or consequence of illness (i.e. reverse
causality).
Recently, longitudinal studies have shown that ele-
vated cytokine levels precede, and so could potentially
cause, depressive symptoms. Based on over 4000 parti-
cipants from the Avon Longitudinal Study of Parents
and Children (ALSPAC) birth cohort, we have shown
that elevated serum levels of IL-6 in childhood increase
risks of developing depressive and psychotic symp-
toms subsequently in adulthood in a linear, dose–
response fashion (Khandaker et al. 2014a). In this
study, evidence for an association persisted after tak-
ing into account effects of sociodemographic factors,
maternal depression and other potential confounders.
A longitudinal association between circulating IL-6
and CRP levels and subsequent development and per-
sistence of depressive symptoms have been reported
from other cohorts (Gimeno et al. 2009; Zalli et al.
2016). Taken together the current evidence indicates
that inﬂammation is unlikely to be merely a conse-
quence of depression or stress (which can cause
immune-activation). Inﬂammation precedes depres-
sion so could be a causal risk factor for the illness.
However, observed association between inﬂamma-
tory markers and depression could still be due to
residual confounding, so more deﬁnitive studies,
such as Mendelian randomization and randomised
controlled trials (RCTs), are needed to establish
whether the association between inﬂammation and
depression is causal. Elevated CRP levels are asso-
ciated with somatic (e.g. fatigue, anorexia, altered
sleep) rather than psychological symptoms of depres-
sion in general population (Jokela et al. 2016) and in
cancer patients who develop depressive symptoms
after interferon treatment (Capuron et al. 2002).
Therefore, focusing on speciﬁc symptoms/group of
symptoms might help to elucidate further the role of
inﬂammation in depression. Animal experimental
studies suggest that inﬂammatory cytokines communi-
cate with the brain using a number of pathways, and
affect mood, cognition and behaviour by altering
neurotransmitter metabolism, activating the hypothal-
amic–pituitary–adrenal (HPA) axis, increasing oxida-
tive stress, and reducing synaptic plasticity possibly
as a result of activation of microglia (a marker of neu-
roinﬂammation) (Raison et al. 2006; Dantzer et al. 2008).
It remains to be seen whether neuroinﬂammation cor-
responds with severity of depression or response to
antidepressant treatment in humans.
Evidence for a role of inﬂammation, atopy and
autoimmunity in psychosis
Epidemiological studies indicate a role of infection,
inﬂammation and autoimmunity in schizophrenia
(Khandaker et al. 2015; Khandaker & Dantzer, 2016).
Schizophrenia is associated with increased prevalence
of various infections, including neurotropic viruses
from the Herpesviridae family, and the intracellular
parasite, Toxoplasma gondii. However, it is unclear
whether increased infection is a result of poor lifestyle,
so more convincing results have come from longitu-
dinal studies. Exposure to a variety of infection during
foetal development, including herpes simplex virus
type 2 (HSV-2), cytomegalovirus (CMV), inﬂuenza,
T. gondii, non-speciﬁc viral/bacterial infection and ele-
vated maternal inﬂammatory marker levels, is asso-
ciated with risk of schizophrenia and related
psychotic illness in adult life, though the strength of
association for each of these exposures vary; reviewed
(Brown & Derkits, 2010; Khandaker et al. 2012, 2013). A
linear, dose–response relationship has been reported
between hospitalisation with a serious infection (CNS
or non-CNS) during childhood and risk of adult psych-
otic disorders (Benros et al. 2011).
Similar to depression, antipsychotic naïve ﬁrst
episode psychosis and acute psychotic relapse are asso-
ciated with increased serum levels of proinﬂammatory
cytokines, such as IL-1β, IL-6, TNF-α and decreased
serum levels of the anti-inﬂammatory cytokine, IL-10,
which tend to normalise after remission of symptoms
with antipsychotic treatment (Miller et al. 2011;
Upthegrove et al. 2014; Goldsmith et al. 2016). Serum
cytokine levels, including IL-6 are associated with ill-
ness severity, duration and anti-psychotic treatment
(Maes et al. 1994; Miller et al. 2011). IL-1β and IL-6
levels have been reported to be elevated in the cerebro-
spinal ﬂuid (CSF) of schizophrenia patients (Garver
et al. 2003). However, it is not clear to what extent per-
ipheral inﬂammation is related to inﬂammatory activ-
ity in the CNS, so further studies are needed.
Recently population-based longitudinal studies have
shown that elevated IL-6 and CRP levels in childhood
or adolescence are associated with increased risk of
developing psychotic symptoms (Khandaker et al.
2014a) and schizophrenia (Metcalf et al. 2017) subse-
quently in adulthood. As with depression, the longitu-
dinal studies indicate that inﬂammation could be a
causal risk factor for psychosis. Adverse experiences
in early-life could be a source of low-grade systemic
inﬂammation in healthy people, as levels of circulating
inﬂammatory markers in adults are associated with
childhood adversity/maltreatment (Baumeister et al.
2016) and sub-optimal foetal environment as indexed
by low birth weight (Tzoulaki et al. 2008). Therefore,
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whether low-grade systemic inﬂammation mediates
the relationship between early-life adversity and
adult depression or psychosis is a hypothesis that
needs testing.
Further support for a role of the immune system in
schizophrenia comes from studies pointing to links
with atopy and autoimmunity (Benros et al. 2011).
There is some evidence that childhood atopic disorders
such as asthma, eczema are associated with increased
risk of psychotic symptoms in adolescence (Khandaker
et al. 2014b) and schizophrenia in adulthood (Pedersen
et al. 2012). The prevalence of autoimmune conditions
is increased in people with schizophrenia and their
unaffected ﬁrst-degree relatives (Eaton et al. 2006).
Schizophrenia is associated with serum antibodies
against dietary antigens, such as gliadin and casein
(Lachance & McKenzie, 2014). Increased autoantibodies
against neuronal cell surface targets, such as
N-methyl-D-aspartate receptor (NMDAR) and compo-
nents of the voltage-gated potassium channel complex,
have been reported in some cases of psychosis in
some (Zandi et al. 2011; Steiner et al. 2013), but not all
studies (de Witte et al. 2015); reviewed (Pollak et al.
2014). Anti-NMDAR antibodies have been typically
associated with the eponymous encephalitis, which is
often associated with psychotic symptoms. Not all
anti-NMADR antibody positive cases of psychosis
have classic features of encephalitis, suggesting these
antibodies might be a cause of psychosis in some peo-
ple. Similarly, elimination of autoantibodies by plasma-
pheresis improves psychotic symptoms in some cases of
ﬁrst episode psychosis (Zandi et al. 2011, 2014).
However, anti-NMDAR antibodies are also increased
in depression and bipolar disorder (Pearlman &
Najjar, 2014). It remains to be established whether anti-
body positive patients differ from antibody-negative
patients in terms of underlying pathology and response
to antipsychotic treatment, and whether immunomodu-
latory treatments are effective in alleviating psychotic
symptoms in this group using RCT. There is limited
data on the relationships between neuronal autoanti-
bodies and other aspects of immunity such as cytokines
and microglial activation. Nevertheless, given these
antibodies are present in about 5% of patients with
ﬁrst episode psychosis (Zandi et al. 2011), some psychi-
atric services in the UK now screen for these antibodies
in new onset cases.
Neuroimaging and genome wide association studies
(GWAS) support a role for the immune system in
schizophrenia. Neuroimaging studies using PET pro-
vide evidence for neuroinﬂammation in patients with
schizophrenia and in persons with subclinical symp-
toms, who are at high risk of psychosis and are related
to at-risk symptom severity (Bloomﬁeld et al. 2016).
Evidence of microglial activation in the entire grey
matter and hippocampus indicates that neuroinﬂam-
mation might contribute to grey matter volume loss
and cognitive deterioration in schizophrenia
(Doorduin et al. 2009). The largest GWAS of schizo-
phrenia to date has shown that in addition to genes
expressed in the brain, schizophrenia is associated
with genes involved in adaptive immunity (CD19
and CD 20 B-lymphocytes) and the major histocom-
patibility complex (MHC) region on chromosome six
(Schizophrenia Working Group of the Psychiatric
Genomics, 2014). The association between schizophre-
nia and the MHC locus arises in part from variations of
the complement component 4 (C4) genes. C4 is a crit-
ical component of the classical complement cascade,
an innate immune system pathway that recognizes
and eliminates pathogens and cellular debris. The
brain expression of C4A is increased in schizophrenia
(Sekar et al. 2016). In mice, C4 tags synapses to be
eliminated by microglial cells (synaptic pruning) that
express C4 receptors during postnatal development.
Excessive complement activity could lead to altered
neurodevelopment as a result of excessive synaptic
pruning.
Inﬂammation and response to psychotropic
treatments
Inﬂammation is associated with poor response to anti-
depressant and antipsychotic treatments. About a third
of depressed patients have elevated circulating CRP
levels (Wium-Andersen et al. 2013) while a third of
patients are antidepressant resistant (Nemeroff,
2007) – this may not be a coincidence. Indeed, activa-
tion of the inﬂammatory system as reﬂected by ele-
vated serum concentrations of IL-6 and other
cytokines predicts poor response to antidepressants
(O’Brien et al. 2007; Carvalho et al. 2013). Patients
who do not respond to selective serotonin reuptake
inhibitors and other antidepressants continue to show
elevated levels of IL-6, CRP and other inﬂammatory
markers (Maes et al. 1997). Findings from patients
with psychosis are similar. Patients with ﬁrst episode
psychosis who do not respond to antipsychotic drugs
have elevated levels of IL-6 and INF-γ at the start of
treatment compared with responders (Mondelli et al.
2015). Furthermore, non-responders continue to show
elevated levels of these inﬂammatory markers after 3
months of antipsychotic treatment compared with
responders (Mondelli et al. 2015). While these ﬁndings
are illuminating, longitudinal studies of inﬂammation
and treatment response based on incident cases are
limited. Inﬂammatory marker levels can be inﬂuenced
by psychological stress, body mass, life style (e.g.
smoking, alcohol use) and some psychotropic drugs.
So further research is needed to understand whether
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and how measuring inﬂammation in clinical setting
could be useful for predicting response to antidepres-
sant/antipsychotic treatment, and for identifying
patients who are likely to beneﬁt from immunomodu-
latory treatments.
It is thought that depressed patients with elevated
inﬂammatory markers display resistance to antide-
pressants because these drugs do not rectify
inﬂammation-related pathologies such as activation
of the kynurenine pathway (Christmas et al. 2011).
Inﬂammatory cytokines such as IFN and IL-6 activate
indoleamine 2,3-dioxygenase (IDO), an enzyme that
shifts metabolism of tryptophan towards kynurenine
(Haroon et al. 2012). Further metabolism of kynurenine
in the brain leads to increased production of neurotoxic
and potentially depressogenic metabolites such as
3-hydroxykynurenine (3-HK) and quinolinic acid. In
mice, lipopolysaccharide-induced systemic inﬂamma-
tion leads to depression-like behaviour through activa-
tion of IDO (O’Connor et al. 2009). Blocking
inﬂammation with minocycline (a broad spectrum
antibiotic) (O’Connor et al. 2009) or an anti-IL-6 mono-
clonal antibody (Hodes et al. 2014) prevents develop-
ment of depression-like behaviour. Pertinent to
psychosis, kynurenic acid is the only naturally occur-
ring NMDAR antagonist in the human CNS
(Schwarcz & Pellicciari, 2002). NMDAR antagonism
and glutamatergic hypofunction have long been pro-
posed to underlie psychotic symptoms and cognitive
dysfunction in schizophrenia (Carlsson & Carlsson,
1990). Indeed, there is evidence that levels of kynure-
nine and kynurenic acid are elevated in the CSF and
brain tissue of schizophrenia patients compared with
healthy controls (Erhardt et al. 2001; Schwarcz et al.
2001). In future, examination of markers of inﬂamma-
tion and IDO activation in peripheral blood and in
CSF in different stages of illness, their relationship
with treatment response would be helpful to under-
stand fully the implications of these ﬁndings for
depression and psychosis.
Effectiveness of immunomodulatory treatment in
depression and psychosis
Anti-inﬂammatory drugs may be helpful for patients
with depression and psychosis. A meta-analysis of
RCTs of non-steroidal anti-inﬂammatory drugs
(NSAIDs), administered as sole treatment or as adjunct
to antidepressants, indicates that they are more effect-
ive than placebo in treating depression (Kohler et al.
2014). The effect size for Celecoxib (a selective cyclooxy-
genase 2 inhibitor) based on 10 RCTs was SMD =−0.29
(95% CI −0.49 to −0.08). However, cyclooxygenase-2
inhibitors increase risk of cardiovascular disease
(Mukherjee et al. 2001), a known comorbidity for
depression, so theiruse in thispatientgroupmaybeprob-
lematic. Besides, it unclear whether improvements in
mood is due to improvements in physical illness or due
to theeffectofNSAIDsonpathwaysother thaninﬂamma-
tion such as glucocorticoid receptor (Nikkheslat et al.
2015).
More recently studies have examined the effective-
ness of cytokine modulators (e.g. anti-cytokine mono-
clonal antibodies and cytokine inhibitors) for
depression. We have conducted a systematic review
and meta-analysis of secondary outcome data on
depressive symptoms from clinical trials of cytokine
modulators in patients with chronic inﬂammatory ill-
nesses. Based on seven RCTs, we have found that cyto-
kine modulators have a signiﬁcant antidepressant
effect; effect size, SMD = 0.40 (95% CI 0.22–0.59)
(Kappelmann et al. 2016). Crucially, improvements in
depressive symptoms are independent of improve-
ments in physical illness, suggesting mood improve-
ment is not merely a by-product of physical
improvement; cytokines may indeed be causally
related to depressive symptoms. Only one RCT to
date has investigated the effectiveness of a monoclonal
antibody using depression as a primary outcome
(Raison et al. 2013). Although overall no beneﬁt of
inﬂiximab (anti-TNF monoclonal antibody) was
observed, the study found that the higher the level of
inﬂammation at the start of trial the greater the
improvement in depressive symptoms by the end of
trial (Raison et al. 2013). Together, these ﬁndings indi-
cate that cytokine modulating drugs could be useful
for depressed patients, particularly those with evi-
dence of inﬂammation, but further work is needed to
establish their efﬁcacy, safety and cost-beneﬁt for treat-
ing depression.
In schizophrenia, a meta-analysis of RCTs of
NSAIDs as adjuncts to antipsychotics has shown
promising results especially for aspirin and non-acetyl
cysteine (Sommer et al. 2014). Dopaminergic drugs,
which include all anti-psychotics currently in use, are
effective in controlling positive symptoms, but cogni-
tive dysfunction and negative symptoms rarely
respond to these drugs. This may indicate fundamental
differences in the mechanism underlying different
types of symptoms. Preclinical studies of peripheral
immune-to-brain communication lend support for a
role of inﬂammation in the pathogenesis of these
difﬁcult-to-treat symptoms (Khandaker et al. 2015;
Khandaker & Dantzer, 2016). In future, targeting
these symptoms with immunological treatment could
be a clinically fruitful strategy. Indeed, minocycline, a
centrally acting tetracyclic anti-inﬂammatory agent,
improves negative symptoms and cognitive function
in schizophrenia (Chaudhry et al. 2012). Celecoxib
may improve cognitive function in early stages of
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schizophrenia (Muller et al. 2002). Recently, a small,
proof-of-concept, open-label study of tocilizumab
(anti-IL-6 receptor monoclonal antibody) as adjunct
to antipsychotic treatment showed improvements in
cognitive function in schizophrenia (Miller et al. 2016),
but more deﬁnitive trials are needed. A subgroup of
patients with depression (Wium-Andersen et al. 2013)
and psychosis (Mondelli et al. 2015) show evidence of
inﬂammation, so RCTs of anti-inﬂammatory drugs
based on ‘inﬂamed’ rather than all patients of depres-
sion/psychosis are likely to be useful.
Transdiagnostic effect of inﬂammation and the
common cause hypothesis
The association between inﬂammation and psychiatric
disorders transcends traditional diagnostic boundaries.
In addition to depression and psychosis, evidence for a
link with inﬂammation exists for a number of disor-
ders, including anxiety (Rossi et al. 2012; Khandaker
et al. 2016), post-traumatic stress disorder (Eraly et al.
2014), autism (Brown et al. 2014) and dementias
(Schmidt et al. 2002). Inﬂammation is likely to be rele-
vant for some, not all, cases of depression/psychosis,
because, as with most chronic illnesses, no risk factor
alone is necessary or sufﬁcient for causing an illness.
Inﬂammation is no different in this regard; evidence
for inﬂammation is seen in a sup-group of patients
with depression and psychosis (Wium-Andersen et al.
2013; Mondelli et al. 2015). One explanation for the
transdiagnostic effect could be that inﬂammation con-
tributes to features common to different psychiatric
syndromes such as fatigue, anhedonia and cognitive
difﬁculties. Furthermore, this lack of speciﬁcity is not
unique to inﬂammation. It is well known that there is
overlap in the genetic risk for depression, schizophrenia
and bipolar disorder. Psychological stress is a common
risk factor for many physical and psychiatric illnesses.
Taking a broader perspective on causal models for
illness, the idea of speciﬁcity of association between a risk
factor and a disease ﬁts well causal models for some ill-
nesses (e.g. Koch’s postulates and Tuberculosis), but
might be problematic in the case of chronic illnesses.
Smoking is associatedwithnumerous illnesses, including
cancersandcardiovasculardiseases.Similarly, inﬂamma-
tion might be a common underlying mechanism for a
number of chronic illnesses of adult life such as depres-
sion, schizophrenia, coronary heart disease and diabetes
mellitus that are highly comorbid with each other. All of
these illnesses are associated with inﬂammation
(Pradhan et al. 2001; Danesh et al. 2004; Khandaker et al.
2014a; Metcalf et al. 2017), which could be linked with
early-life factors inﬂuencing inﬂammatory regulation,
such as impaired foetal development or childhood mal-
treatment. This idea is consistentwith the common-cause
or developmental programming hypothesis by David
Barker (Barker et al.1993a).Developmentalprogramming
refers to permanent alteration in physiological system(s)
following exposure to adversity during a speciﬁc ‘devel-
opmental window’. The resulting physiological altera-
tions, in combination with genetic and/or other
environmental factors, can increase risks of several
diseases in adulthood. Empirical evidence from longitu-
dinal studies supports the developmental programming
hypothesis. Low birth weight (a marker of suboptimal
foetal development) and childhood maltreatment are
associated with increased circulating CRP levels
(Tzoulaki et al. 2008) as well as risks of heart disease, dia-
betesmellitus, depressionand schizophrenia (Barker et al.
1993b; Abel et al. 2010). Indeed, there is evidence that
inﬂammation moderates the association between child-
hood maltreatment and risk of depression in adulthood
(Danese et al. 2008). In future, population-based epi-
demiological, clinical and experimental studies are
needed to understand whether and how inﬂammation
contributes to the comorbidity between chronic cardio-
metabolic and psychiatric illnesses of adult life.
Experimental studies would be particularly useful to
understand how early-life adversity might ‘programme’
the immune system.
Conclusions
Pathophysiologic explanations and pharmacotherapy
for major psychiatric disorders such as depression
and schizophrenia are predicated on monoamine neu-
rotransmitters. However, heterogeneity in clinical pres-
entation, illness course and treatment response suggest
other mechanisms are involved. A better understand-
ing of the role of immune system could be paradigm
changing for psychiatry by providing novel mechan-
isms and treatments for these disorders, which are
among leading causes of disability worldwide. The
ﬁeld now needs studies to investigate causality of asso-
ciation and RCTs of novel immunotherapies for
depression and psychosis. In future, immunotherapeu-
tic strategies could include immune-phenotyping of
patients to predict treatment response and anti-
inﬂammatory treatment for patients with evidence of
inﬂammation. Shifting the focus of research from syn-
drome to symptom (or constellation of symptoms) may
help to fully elucidate the role of immune system in the
aetiology of psychiatric disorders. Accumulating evi-
dence from preclinical studies suggests inﬂammation
is a key mechanism underlying cognition and behav-
iour, which needs to be translated into human studies
of affective and cognitive neuroscience. A clearer
understanding of the immunological aspects of psychi-
atric disorders may lead to novel approaches to diag-
nosis and treatment but would require close
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collaborations between clinicians and researchers to
deliver high-quality translational research.
Immunopsychiatry: Key facts
• Depression is common in people with a chronic
inﬂammatory illness, and immuno-activation
leads to depressive symptoms in patients and
healthy volunteers
• Schizophrenia and related psychotic disorders
are associated with prenatal and childhood
infections, atopic disorders and autoimmunity
• Elevated circulating inﬂammatory markers
increase future risk of depression and psych-
osis in healthy people suggesting inﬂamma-
tion might cause these disorders
• Circulating inﬂammatory markers are elevated
in acute depression and psychosis, which tend
to normalise after recovery, but continue to be
elevated in treatment resistant cases
• There is evidence of neuroinﬂammation in
schizophrenia as demonstrated by activation
of microglia in patients as well as those who
are at risk of developing the illness
• Anti-NMDA receptor and anti-VGKC anti-
bodies may be responsible for about 5% of
all cases of psychosis
• Elevated circulating inﬂammatory markers
are associated with poor response to anti-
depressant and antipsychotic treatment
• Measuring circulating inﬂammatory markers
may aid treatment decisions
• Emerging evidence indicates anti-inﬂammatory
agents may be effective treatments for patients
with depression and psychosis particularly
those with evidence of inﬂammation
• Inﬂammation might be a common mechanism
underlying the comorbidities between depres-
sion, schizophrenia, coronary heart disease
and diabetes mellitus
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